Department of Pharmaceutics, Jamia Hamdard, Hamdard Nagar, New Delhi, India.
Curr Drug Deliv. 2011 Nov;8(6):691-702. doi: 10.2174/156720111797635504.
Poor solubility remains a major challenge for pharmaceutical industry, which is now considered to be an area of prime importance in the field of biomedical research. Approximately 40% new molecular entities (NMEs) synthesized in pharmaceutical R with advanced combinatorial chemistry and computer aided drug designing (CADD) approaches suffer from poor solubility and bioavailability related issues. Apart from these presence of intestinal tight junctional epithelial cells, transporters and enzymatic barriers further reduces the oral absorption of drugs. Implication of the novel lipid based nanocarriers and nanomaterials like dendrimers and carbon nanotubes as a delivery system can effectively enhance the oral bioavailability of drugs by breaching the barriers, and resolve all critics related to solubility and bioavailability. Thus prime objectives of this review are to give in-depth knowledge and critical appraisal on the barriers for poor oral bioavailability of drugs, along with various novel formulation approaches used for bioavailability enhancement such as lipid based formulations, nanosizing techniques, complexation with polymers and nanomaterials like dendrimers, carbon nanotubes, and penetration enhancers. Also it gives a brief account on in vitro, in vivo screening methods used for assessment of oral bioavailability, and regulatory considerations for the approval.
溶解度差仍然是制药行业面临的主要挑战,现在被认为是生物医学研究领域的一个首要重点。在制药 R 中,大约有 40%的新分子实体(NMEs)采用先进的组合化学和计算机辅助药物设计(CADD)方法合成,它们存在溶解度和生物利用度相关问题。除了这些之外,肠道紧密连接上皮细胞、转运体和酶屏障的存在进一步降低了药物的口服吸收。新型基于脂质的纳米载体和纳米材料(如树枝状大分子和碳纳米管)作为递送系统的应用,可以通过突破这些屏障,有效地提高药物的口服生物利用度,并解决与溶解度和生物利用度相关的所有问题。因此,本篇综述的主要目的是深入了解药物口服生物利用度差的各种障碍,并对其进行评价,同时还介绍了用于提高生物利用度的各种新型制剂方法,如基于脂质的制剂、纳米化技术、与聚合物的络合以及纳米材料(如树枝状大分子、碳纳米管和渗透增强剂)。此外,本文还简要介绍了用于评估口服生物利用度的体外和体内筛选方法,以及获得批准的监管考虑因素。